WARNER BRENT (President, Gene Therapy) received a stock award from POSEIDA THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 3/4/2024ACC: 0000950170-24-024920
Officer· President, Gene Therapy
Since Feb 2022
+156.70K
Net shares
Net buyer
$147.6K
Total sold
0
Open market trades
0B · 0S
3
Total transactions
192.44K acquired · 35.74K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+80.74K
Price / share
—
Trade value
—
% of position
21.6%
3/1/2024
374.04K→454.78K
Common Stock
Direct
Shares
−35.74K
Price / share
$4.13
Trade value
$147.60K
% of position
7.9%
3/1/2024
454.78K→419.04K
Total
Net shares
+45K
Net value
-$147.60K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2024 | A · Award | +80.74K | — | — | 21.6% | 374.04K | 454.78K |
| Common Stock Direct | 3/1/2024 | F · Tax Withholding | −35.74K | $4.13 | $147.60K | 7.9% | 454.78K | 419.04K |
| Total | +45K | -$147.60K | ||||||
Derivative Transactions1
Employee Stock Option (Right to Buy)
Direct
Converts to
Common Stock
111.70K shares
Shares
+111.70K
Strike price
4.13
Held after
111.70K
Exercisable
—
3/1/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) Direct | Common Stock111.70K shares | 3/1/2024 | A · Award | +111.70K | 4.13 | — | 111.70K |